Karina Dias Teixeira
Research Subjects
Research Interests
Karina Dias Teixeira has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aurora Diotallevi
Department of Biomolecular Sciences, University of Urbino Carlo Bo
1 shared publication - Berthal Huseyin Aktas
Division of Hematology, Brigham and Women's Hospital & Harvard Medical School, Boston, MA, USA
1 shared publication - Jorge Mansur Medina
Laboratory of Molecular Parasitology, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
1 shared publication - José Vitorino dos Santos
Instituto de Biofísica Carlos Chagas Filho, Brazil
1 shared publication - Luca Galluzzi
Department of Biomolecular Sciences, University of Urbino Carlo Bo
1 shared publication - Michael Chorev
Brigham and Women's Hospital, Division of Hematology, 4 Balckfan Circle. HIM 7, Boston, MA 02115, USA; Harvard Medical School, Division of Hematology, 4 Balckfan Circle. HIM 7, Boston, MA 02115, USA
1 shared publication
Latest Publications
- Open Access
- 26 September 2023
- Published by MDPI AG in Preprints.org
Activity of the Di-Substituted Urea-Derived Compound I-17 in Leishmania Infections
Protein synthesis has been a very rich target for developing classes of drugs to control prokaryotic and eukaryotic pathogens. Despite the development of new drug formulations, treating human cutaneous and visceral Leishmaniasis still needs significant improvement due to considerable side effects and low adherence to the usual treatment regimen. In this work, we show that the di-substituted urea-derived compound I-17 is effective in inhibiting the promastigote forms and intracellular amastigotes of the Leishmania (L.) amazonensis and L. infantum species, in addition to exhibiting low macrophage cytotoxicity. We also show a potential immunomodulatory effect of I-17 in infected macrophages, which exhibited increased expression of inducible Nitric Oxide Synthase (NOS2) and Nitric Oxide (NO) production. Our data suggest that I-17 and new derivatives of this compound may be helpful in developing new drugs for treating leishmaniasis.
- 26 September 2023
- Published by MDPI AG in Preprints.org
Open AccessActivity of the Di-Substituted Urea-Derived Compound I-17 in Leishmania Infections
Protein synthesis has been a very rich target for developing classes of drugs to control prokaryotic and eukaryotic pathogens. Despite the development of new drug formulations, treating human cutaneous and visceral Leishmaniasis still needs significant improvement due to considerable side effects and low adherence to the usual treatment regimen. In this work, we show that the di-substituted urea-derived compound I-17 is effective in inhibiting the promastigote forms and intracellular amastigotes of the Leishmania (L.) amazonensis and L. infantum species, in addition to exhibiting low macrophage cytotoxicity. We also show a potential immunomodulatory effect of I-17 in infected macrophages, which exhibited increased expression of inducible Nitric Oxide Synthase (NOS2) and Nitric Oxide (NO) production. Our data suggest that I-17 and new derivatives of this compound may be helpful in developing new drugs for treating leishmaniasis.